KR101007151B1 - 흡입용 분말 제형 - Google Patents

흡입용 분말 제형 Download PDF

Info

Publication number
KR101007151B1
KR101007151B1 KR1020047015822A KR20047015822A KR101007151B1 KR 101007151 B1 KR101007151 B1 KR 101007151B1 KR 1020047015822 A KR1020047015822 A KR 1020047015822A KR 20047015822 A KR20047015822 A KR 20047015822A KR 101007151 B1 KR101007151 B1 KR 101007151B1
Authority
KR
South Korea
Prior art keywords
tiotropium
powder formulation
powder
suspending agent
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047015822A
Other languages
English (en)
Korean (ko)
Other versions
KR20040098049A (ko
Inventor
롤프 반홀처
만프레트 그라울리히
크리스티안 쿨린나
안드레아스 마테스
헬무트 마이스너
페터 지거
페터 슈페흐트
미하엘 트룬크
Original Assignee
베링거 잉겔하임 파르마 게엠베하 운트 코 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 filed Critical 베링거 잉겔하임 파르마 게엠베하 운트 코 카게
Publication of KR20040098049A publication Critical patent/KR20040098049A/ko
Application granted granted Critical
Publication of KR101007151B1 publication Critical patent/KR101007151B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
KR1020047015822A 2002-04-04 2003-03-28 흡입용 분말 제형 Expired - Fee Related KR101007151B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02007634 2002-04-04
EP02007634.5 2002-04-04
PCT/EP2003/003253 WO2003084509A1 (en) 2002-04-04 2003-03-28 Powder formulations suitable for inhalation

Publications (2)

Publication Number Publication Date
KR20040098049A KR20040098049A (ko) 2004-11-18
KR101007151B1 true KR101007151B1 (ko) 2011-01-13

Family

ID=28685839

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047015822A Expired - Fee Related KR101007151B1 (ko) 2002-04-04 2003-03-28 흡입용 분말 제형

Country Status (19)

Country Link
US (2) US6881422B2 (cg-RX-API-DMAC7.html)
EP (1) EP1494648B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005526103A (cg-RX-API-DMAC7.html)
KR (1) KR101007151B1 (cg-RX-API-DMAC7.html)
CN (1) CN100360116C (cg-RX-API-DMAC7.html)
AT (1) ATE339951T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003221531B2 (cg-RX-API-DMAC7.html)
BR (1) BR0308984A (cg-RX-API-DMAC7.html)
CA (1) CA2479919C (cg-RX-API-DMAC7.html)
DE (1) DE60308497T2 (cg-RX-API-DMAC7.html)
DK (1) DK1494648T3 (cg-RX-API-DMAC7.html)
ES (1) ES2272968T3 (cg-RX-API-DMAC7.html)
IL (2) IL163736A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04009583A (cg-RX-API-DMAC7.html)
NZ (1) NZ536277A (cg-RX-API-DMAC7.html)
PL (1) PL207752B1 (cg-RX-API-DMAC7.html)
RU (1) RU2004132222A (cg-RX-API-DMAC7.html)
WO (1) WO2003084509A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200406911B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1712A (en) 2000-10-12 2007-01-24 Boehringer Ingelheim Pharma Novel tiotropium-containing inhalation powder
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US7244415B2 (en) * 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
DK1682541T3 (da) 2003-11-03 2010-06-28 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af tiotropiumsalte

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034778A1 (en) * 1997-12-31 1999-07-15 Leiras Oy A method for making a pharmaceutical formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2540633A1 (de) * 1975-09-12 1977-04-28 Boehringer Sohn Ingelheim Neue quartaere n-beta-substituierte benzilsaeure-n-alkyl-nortropinester und verfahren zu deren herstellung
DE3211185A1 (de) * 1982-03-26 1983-09-29 Boehringer Ingelheim KG, 6507 Ingelheim Neue quartaere 6,11-dihydro-dibenzo-(b,e)-thiepin-11-n-alkyl- norscopinether und verfahren zu deren herstellung
DE3215493A1 (de) * 1982-04-26 1983-11-03 Boehringer Ingelheim KG, 6507 Ingelheim Neue zwischenprodukte, verfahren zu ihrer herstellung und ihre verwendung
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5770738A (en) * 1992-03-05 1998-06-23 Boehringer Ingelheim Kg Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
DE19515625C2 (de) * 1995-04-28 1998-02-19 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
AP1712A (en) * 2000-10-12 2007-01-24 Boehringer Ingelheim Pharma Novel tiotropium-containing inhalation powder
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10064816A1 (de) * 2000-12-22 2002-06-27 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Anticholinergikums
US6506900B1 (en) * 2001-01-31 2003-01-14 Boehringer Ingelheim Pharma Ag Process for preparing a scopine ester intermediate
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US6482429B1 (en) * 2001-06-20 2002-11-19 Boehringer Ingelheim Pharmaceuticals, Inc. Stable powder inhalation dosage formulation
DE10141377A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
DE10141376A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034778A1 (en) * 1997-12-31 1999-07-15 Leiras Oy A method for making a pharmaceutical formulation

Also Published As

Publication number Publication date
JP2005526103A (ja) 2005-09-02
BR0308984A (pt) 2005-02-09
CA2479919A1 (en) 2003-10-16
EP1494648A1 (en) 2005-01-12
EP1494648B1 (en) 2006-09-20
US6881422B2 (en) 2005-04-19
AU2003221531B2 (en) 2008-10-23
KR20040098049A (ko) 2004-11-18
HK1078795A1 (zh) 2006-03-24
RU2004132222A (ru) 2005-10-10
IL163736A (en) 2010-12-30
MXPA04009583A (es) 2005-01-11
PL207752B1 (pl) 2011-01-31
CN1646099A (zh) 2005-07-27
US20050009857A1 (en) 2005-01-13
ES2272968T3 (es) 2007-05-01
WO2003084509A1 (en) 2003-10-16
ZA200406911B (en) 2006-07-26
ATE339951T1 (de) 2006-10-15
NZ536277A (en) 2006-03-31
US20040029907A1 (en) 2004-02-12
DK1494648T3 (da) 2006-12-27
AU2003221531A1 (en) 2003-10-20
PL371267A1 (en) 2005-06-13
DE60308497D1 (de) 2006-11-02
IL163736A0 (en) 2005-12-18
DE60308497T2 (de) 2007-02-22
CN100360116C (zh) 2008-01-09
CA2479919C (en) 2011-05-17

Similar Documents

Publication Publication Date Title
AU757008B2 (en) Novel tiotropium-containing inhalation powder
AU2003288226B2 (en) Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate
JP2005526776A (ja) 臭化チオトロピウムの結晶性微粒子
EP1429722A1 (de) Aufstreuverfahren zur herstellung von pulverformulierungen
US6881422B2 (en) Powder formulations containing tiotropium suitable for inhalation
AU2003294714B2 (en) Pulverulent formulation for inhalation containing tiotropium
HK1078795B (en) Powder formulations suitable for inhalation

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20131230

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20141229

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160105

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160105